Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC
Executive Summary
Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.
You may also be interested in...
AstraZeneca's 13 Outcomes-Based Contracts Show “Proactive" Engagement On New Models
AstraZeneca VP-Market Access Rick Suarez talks about challenges and opportunities in the emerging area of innovative outcomes-based reimbursement contracts, and specifically two new contracts with Harvard Pilgrim for Bydureon and Brilinta.
Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim
Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.
Outcomes-Based Contracts Aren’t So Easy, Harvard Pilgrim Cautions
Value-based, risk-sharing reimbursement contracts were a hot topic at ISPOR, but Harvard Pilgrim Health Care Chief Medical Officer Michael Sherman cautioned that finding the right drug and the right pharma partner to work with are challenging.